Pharmaceutical Drug Delivery Market
Pharmaceutical Drug Delivery Market By Administration Route (Oral, Injectable, Topical, Ocular, Nasal, Transmucosal & Implantable, Pulmonary, Transdermal Patch), Application (Cancer, Diabetes, Cardiovascular), Facility of Use - Global Forecast to 2031
PHARMACEUTICAL DRUG DELIVERY MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global pharmaceutical drug delivery market is projected to grow from USD 2,152.45 billion in 2026 to USD 2,922.82 billion by 2031, at a CAGR of 6.3% during the forecast period. The market was valued at USD 2,077.13 billion in 2025. The rise in demand for advanced drug delivery systems due to the rapid growth of biologics and biosimilars worldwide is driving the market, leading to investments in more drug dosage forms and large-volume injectable technologies. Besides, the increasing number of chronic diseases such as cancer, diabetes, and autoimmune disorders worldwide is also urging the demand for self administration and patient centric delivery solutions. The transition to home-based and wearable drug delivery systems is helping patients stick to their treatments and at the same time, increasing the usage of smart, connected, and sensor, enabled injectors. The high research activity in top drug delivery and pharmaceutical sciences journals also indicates a strong interest in innovative drug delivery technologies. Continuing improvements in prefilled syringes, transdermal delivery, and connected devices, as well as higher investments in pharmaceutical research, still act as a source of market growth.
KEY TAKEAWAYS
-
By Route of AdministrationBy route of administration, the injectable drug delivery segment dominated the market with 40.3% market share in 2025.
-
By ApplicationBy application, the injectable drug delivery application segment is expected to register the highest CAGR of 7.9% between 2026 and 2031.
-
By Facility of UseBy facility of use, the formulations segment is expected to dominate the market, with a share of 59.3% in 2025.
-
Competitive Landscape - Key PlayersJohnson & Johnson Services (US), Pfizer Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), BD (US), Novartis AG (Switzerland), were identified as the star players in the pharmaceutical drug delivery market, given their extensive global reach and comprehensive product portfolios.
-
Competitive Landscape - StartupsAdhexPharma (France), and Rusan Pharma (India) have distinguished themselves among startups and SMEs due to their innovations in drug delivery systems, novel delivery technologies, and specialized formulation capabilities focused on improving patient convenience and therapeutic outcomes.
The global pharmaceutical drug delivery market is witnessing a steady growth, which can be attributed to the increasing demand for complex biologics that necessitate advanced injectable, transdermal, inhalation, and large-volume drug delivery systems. The trend of self administration as patients with chronic diseases manage their conditions at home is also a key factor behind this rise. Besides, rapid progress in wearable injectors, smart prefilled syringes, and smart drug delivery systems that enhance adherence and enable real-time monitoring is paving the way for further growth. Pharmaceutical companies are dedicating a considerable portion of their budget to new drug formulations that include long acting injectables, nanoparticle based delivery, controlled release dosage forms, and novel drug delivery systems to increase drug efficacy and patient comfort. At the same time, regulatory measures aimed at minimizing medication errors and ensuring the safety of device drug combinations are still the main factors encouraging the use of advanced drug delivery technologies that are easy to use in healthcare facilities.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The massive trends and transformations, as well as the shift from traditional small molecule therapies to biologics, have begun to trigger a paradigm shift in the global pharmaceutical drug delivery market. This paradigm shift is characterized by heavy investments in next-generation injectable platforms, wearable drug delivery systems, and biologic-compatible technologies in various geographies. This paradigm change is also being accompanied by the rapid proliferation of connected and sensor, equipped devices that enable digital therapy management, electronic health system integration, and remote patient monitoring, as well as the growing worldwide trend for self-administration to reduce clinic and hospital visits. Besides that, groundbreaking medical devices such as on-body injectors, microneedle patches, nanoparticle based carriers, and smart inhalers are transforming drug delivery by providing more precise dosage, better patient adherence, and greater convenience for patients. Nevertheless, global supply-chain challenges, sterility requirements, and stricter regulatory expectations for drug–device combination products are compelling pharmaceutical manufacturers to adopt more automated, user-centric, and technology-integrated delivery platforms.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising global demand for biologics, biosimilars, and complex therapies
-
Increasing shift toward self-administration and home-based care worldwide
Level
-
High development costs and stringent global regulatory requirements
-
Infections associated with needlestick injuries
Level
-
Geographic expansion into emerging markets
-
Integration with digital health & remote monitoring
Level
-
Pricing pressure by governing bodies
-
Limited patient training and adherence issues for advanced self-administration and wearable delivery systems
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing shift toward self-administration and home-based care worldwide
At present, patients as well as the healthcare sector are moving toward home care for the treatment of chronic diseases due to the convenience and cost-effectiveness. This has resulted in an increased demand for self-administered drug delivery systems such as auto-injectors, on-body injectors, and wearable injectors. These devices help patients in following a regular regimen and are a part of the drug delivery system.
Restraint: High development costs and stringent global regulatory requirements
The development of advanced drug delivery systems involves complex R&D, the use of specialized materials, large-scale sterile manufacturing, and quality control, all of which contribute to a substantial increase in the cost of production of biologics, next-generation injectables, and combination products. These high costs are further exacerbated by stringent and varied global regulatory requirements in the US, Europe, and Asia, where formulations and device-drug combinations are required to adhere to stringent requirements for safety, efficacy, and performance.
Opportunity: Increasing adoption of long-acting and targeted delivery technologies
Globally, there has been a rise in the use of long-acting injectables, nanoparticle formulations, microneedle patches, and targeted drug delivery systems. Such technologies help improve drug bioavailability, reduce the number of times drugs have to be taken, and increase treatment specificity, especially in the cases of cancer, neurology, and immunology. More and more investment in precision medicine and advanced formulations is helping to create big opportunities for companies which are engaged in the development of next generation drug delivery technologies.
Challenge: Complex regulatory environments, supply chain, and sterility issues
The global pharmaceutical drug delivery industry is challenged by complex regulatory environments, long approval cycles, and high quality standards for device-drug combination products. The regulatory environment poses a challenge to the development of new drug delivery systems. On the other hand, the industry is also challenged by high sterility standards, cold chain logistics, and a delicate global supply chain that is, at times, threatened by component shortages and supply chain disruptions.
PHARMACEUTICAL DRUG DELIVERY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Offers advanced delivery platforms such as osmotic oral systems, transdermal patches, implantable pumps, liposomal systems, and controlled-release technologies across major therapeutic areas | Controlled and targeted release for improved adherence | Broad expertise across oral, transdermal, implantable, and injectable formats | Support for biologics and long-acting therapies |
 |
Provides oral solids, injectables, sustained-release, liposomal, and nanoparticle-based delivery systems; invests in delivery for mRNA and complex biologics | Support for consistent and flexible delivery of small molecules and biologics | Strong R&D and global manufacturing | Rapid commercialization of new delivery technologies |
 |
Specializes in implantable, port-based, and sustained-release platforms; strong presence in injectable delivery for oncology, immunology, and ophthalmology | Enhanced localized/sustained administration | Reduced dosing frequency | Improved compliance | Expertise in biologics and ADCs | Support for high-value targeted therapies |
 |
Provides prefillable syringes, safety systems, autoinjectors, pen injectors, and BD Libertas wearable injector supporting combination product development and self-administration | Low development risk | Accelerated market entry | Strong manufacturing | Safety features | Improved adherence and support home-based delivery |
 |
Develops drug–device and advanced delivery systems including inhalation platforms, injectable biologics, and subcutaneous technologies; expanding infrastructure for radioligand and cell-based therapies | Improved adherence and outcomes | Expertise in complex therapies | Precision dosing | Regulatory readiness | Global supply reliability |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The pharmaceutical drug delivery market is driven by major pharmaceutical companies, niche device manufacturers, CDMOs, healthcare institutions, and government authorities across different geographies. The market is witnessing a transformation to cater to the increasing demand for safer, more convenient, and patient-friendly drug delivery systems. Heavy investments in biologics, nanotechnology, and controlled release are driving the innovations in injectables, inhalation devices, transdermal systems, and self-administration devices. Government authorities, such as the US FDA, EMA, PMDA, and the China, and Indian regulatory authorities are facilitating this transition by improving the regulations for combination products and quality. On the contrary, the increasing incidence of chronic diseases, aging population, and the trend toward home-based care are driving the demand for wearable injectors, long-acting formulations, and digital drug delivery devices, thus transforming the global drug delivery market.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Pharmaceutical Drug Delivery Market, By Route of Administration
The injectable drug delivery segment held the largest market share in the global pharmaceutical drug delivery market in 2025. A considerable part of the market growth will be contributed from biologics, monoclonal antibodies, vaccines, and other large, molecule therapies that need parenteral administration. Moreover, the escalating global burden of chronic diseases, including cancer, diabetes, autoimmune disorders, and cardiovascular diseases, is boosting the demand for reliable, precise, and efficient dosing solutions, wherein injectables have an added advantage over oral routes. Worldwide, patients and healthcare providers prefer self, administration tools, e.g., autoinjectors, prefilled syringes, pen injectors, and wearable injectors, which facilitate convenience and fewer clinical visits. Importance of safety engineered devices, needle-free injectors, and on-body delivery platforms in this segment can be seen in that these technologies improve adherence, usability, and treatment experience in various healthcare environments.
Pharmaceutical Drug Delivery Market, By Application
In the pharmaceutical drug delivery market, by application, injectable drug delivery is expected to be the fastest-growing segment during the forecast period. This segment is driven by the rising prevalence of chronic and complex diseases such as cancer, autoimmune disorders, and metabolic conditions, which increasingly rely on injectable therapies for effective treatment. Injectables enable accurate dosing, faster therapeutic action, and higher bioavailability, making them essential for biologics, vaccines, and advanced therapies including gene and cell treatments. The strong expansion of oncology, immunology, and infectious disease treatments largely dependent on parenteral administration is further accelerating demand across these application areas. Additionally, advancements in drug delivery technologies, such as prefilled syringes, autoinjectors, and long-acting injectables, are improving patient compliance and supporting the shift toward self-administration and home care.
Pharmaceutical Drug Delivery Market, By Facility of Use
In the pharmaceutical drug delivery marker, the formulations segment—comprising hospitals, ambulatory surgical centers/clinics, home care settings, diagnostic centers, and long-term care facilities—accounted for the largest market share in 2025 and is expected to maintain its dominance during the forecast period. This is because these settings represent the final point of care where drug products are administered to patients, directly driving consumption volumes across all routes of administration. Hospitals hold the largest share within this segment due to their advanced infrastructure, availability of skilled healthcare professionals, and ability to handle complex therapies, such as injectables, biologics, oncology treatments, and critical care medications. The growing burden of chronic diseases, increasing surgical procedures, and rising hospital admissions further strengthen demand in this setting.
REGION
Asia Pacific to be fastest-growing region in global pharmaceutical drug delivery market during forecast period
The Asia Pacific pharmaceutical drug delivery market is expected to witness the fastest growth rate during the forecast period supported by the increasing healthcare expenditure, the setting up of pharmaceutical manufacturing plants, and the growing application of advanced therapies in China, India, Japan, and South Korea. Additionally, the need for advanced drug delivery systems, especially for biologics, biosimilars, and specialty medicines, is driven by the rapid urbanization, the growing middle class population, and the broader insurance coverage. More spending on hospitals, specialty clinics, and integrated care centers is leading to an increase in the use of injectable, inhalation, transdermal, and self, administrated delivery devices such as autoinjectors and wearable injectors. The excellent biosimilar production capabilities and the growth of local R&D contribute significantly to the support of cost, efficient delivery technology adoption in the region.
PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX
In the pharmaceutical drug delivery formulations market matrix, the star players are Johnson & Johnson, Pfizer, Roche, and Novartis. These players are highly benefited from their R&D capabilities, various delivery modes, and leadership in biologics, oncology, vaccines, and chronic disease therapies. Their position of dominance is supported by especially trustworthy technologies such as sustained release technologies, implantable devices, smart injectors, lipid nanoparticle technologies, and drug combinations. These players are also benefited from large-scale manufacturing, regulatory knowledge, and tech support. On the other hand, the emerging leaders in the industry are Boehringer Ingelheim International GmbH. These players are making rapid progress by concentrating on particular delivery modes. These delivery modes include microneedles, wearables, nanoparticle technologies, implants for ocular delivery, and innovations for biologic delivery through subcutaneous. In addition to the large-scale suppliers, niche technology suppliers and medium-scale players are also expanding their knowledge in inhalation technologies, skin patches, depot injections, and digital delivery devices. The convergence of resources and capabilities of established players and the innovative and technology-driven strengths of new entrants is changing the pharmaceutical drug delivery market into a highly competitive and rapidly expanding market. Similarly, in pharmaceutical drug delivery device market, the star players are BD and Stevanato Group and the emerging leaders in this market are SHL Medical and others.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Johnson & Johnson (US)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche (Switzerland)
- Pfizer Inc. (US)
- Eli Lilly and Company (US)
- GSK plc (UK)
- AbbVie Inc. (US)
- Merck & Co. (US)
- Bausch Health Companies Inc.(Canada)
- Bayer AG (Germany)
- Amgen, Inc. (US)
- Boehringer Ingelheim International GmbH (Germany)
- AstraZeneca (UK)
- Company Name (Devices)
- BD (US)
- Cardinal Health (US)
- B.Braun SE (Germany)
- Terumo Corporation (Japan)
- Nipro (Japan)
- Stevanato Group (Italy)
- Gerresheimer AG (Germany)
- West Pharmaceutical Services (US)
- Ypsomed (Switzerland)
- SHL Medical (Switzerland)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 2,077.13 Billion |
| Market Forecast in 2031 (Value) | USD 2,922.82 Billion |
| Growth Rate | CAGR of 6.3% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion), Volume (Ten Thousand Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, the Middle East & Africa |
WHAT IS IN IT FOR YOU: PHARMACEUTICAL DRUG DELIVERY MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis |
|
Enabled clients to identify which drug delivery technologies are most beneficial across global therapeutic segments considering efficacy, patient convenience, and adherence. Highlighted region-specific maturity to guide adoption of long-acting injectables, combination products, or nano-based platforms. Helped clients benchmark innovation levels (e.g., mRNA delivery, smart injectors) across regions and align product development with global needs in chronic disease management, biologics administration, and home-based self-treatment. |
| Company Information |
|
Included comparative positioning, technological strengths, and partnership ecosystems across global pharma and drug-device integrators. Supported supplier evaluation for prefilled syringes, autoinjectors, biologic-ready containers, and advanced delivery technologies. Guided clients in selecting partners for licensing, co-development, outsourcing, or biologics delivery innovation. Expanded understanding of long-term company strategies, competitive differentiation, and regional leadership across high-growth therapeutic segments worldwide. |
| Geographic Analysis |
|
Supported strategic decision-making by pinpointing high-growth global delivery modalities (injectables, autoinjectors, wearable pumps, nanoparticle systems). Assisted in evaluating localization opportunities, supply-chain expansion, and optimal regions for manufacturing or partnerships. Enabled clients to identify global patient-preference trends, driven by biologics, aging populations, and rising home-care delivery. Country-level analysis strengthened clients’ ability to expand in diverse international markets with tailored entry and growth strategies. |
RECENT DEVELOPMENTS
- May 2026 : Johnson & Johnson announced that the US Food and Drug Administration (FDA) approved ICOTYDE (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.
- March 2026 : Novartis announced that it has entered an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor, exploring a next-generation approach for the treatment of patients with HR+/HER2- breast cancer and potentially other solid tumor indications.
- December 2025 : US Food and Drug Administration (FDA) approved F. Hoffmann-La Roche's CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab), as a subcutaneous (SC) formulation, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
Secondary Research
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the veterinary imaging market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
Primary Research
In the primary research process, a range of sources from the supply and demand sides were used to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the pharmaceutical drug delivery market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes, and contract research organizations.
A breakdown of the primary respondents is provided below:
Note: C-level executives include CEOs, COOs, CTOs, and VPs. Other designations include sales, marketing, and product managers.
Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the pharmaceutical drug delivery market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Pharmaceutical Drug Delivery Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
Pharmaceutical drug delivery is a method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery offer several benefits, such as ease of use, convenience, and patient compliance. Drug delivery technologies are used for the targeted delivery and/or controlled release of therapeutic agents.
Key Stakeholders
- Pharmaceutical manufacturing companies
- Original equipment manufacturing companies
- Suppliers and distributors of pharmaceutical products and medical devices
- Healthcare service providers
- Teaching hospitals and academic medical centers
- Health insurance players
- Government bodies/municipal corporations
- Regulatory bodies
- Medical research institutes
- Business research and consulting service providers
- Venture capitalists
- Market research and consulting firms
Report Objectives
- To describe and forecast the global pharmaceutical drug delivery market, by route of administration, application, facility of use, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, Netherlands, Denmark, Sweden, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Thailand, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and Rest of Latin America), and the Middle East & Africa [Turkey, GCC Countries (Saudi Arabia, the UAE and Rest of GCC) and Rest of Middle East & Africa]
- To profile the key market players and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global pharmaceutical drug delivery market
Customization Options
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global pharmaceutical drug delivery market report.
Product Analysis
- Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.
Company Information
- Detailed analysis and profiling of additional market players (up to 5 players)
Geographic Analysis
- Further breakdown of the Rest of Europe pharmaceutical drug delivery market into Austria, Switzerland, Finland, Sweden, Poland, and Portugal, among other countries
- Further breakdown of the Rest of Asia Pacific pharmaceutical drug delivery market into Vietnam, Philippines, Singapore, Malaysia, and Indonesia, among other countries
- Further breakdown of the Rest of Latin America pharmaceutical drug delivery market into Chile and Colombia, among other countries.
Country-Level Volume Analysis By Product
- Quantifies volumes by major service types for selected countries to show demand patterns. Product Type Market Share Analysis (Top 5 Players).
By Route Of Administration Market Share Analysis (Top 5 Players)
- Route of Administration Market Share Analysis (Top 5 Players).
Any Consult/Custom Requirements As Per Client Requests
- Provides tailored analyses, datasets, and deliverables based on specific client briefs..
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Drug Delivery Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in Pharmaceutical Drug Delivery Market
Logan
Jun, 2026
I reviewed the Pharmaceutical Drug Delivery Market report to evaluate how shifting formulation technologies are reshaping our pipeline prioritization, especially for complex biologics and controlled-release systems..
Skye
Jun, 2026
While going through the Pharmaceutical Drug Delivery Market insights, I focused on the technical segmentation of oral, injectable, and transdermal systems to understand where device–drug integration is creating real development bottlenecks in manufacturing scalability..
Ryker
Jun, 2026
After analyzing the Pharmaceutical Drug Delivery Market outlook, I assessed the investment implications around sustained-release and targeted delivery platforms, particularly in terms of regulatory complexity and long-term commercialization feasibility..
Gregory
Mar, 2022
Looking forward to gain more insights on the global Pharmaceutical Drug Delivery Market.
Alexander
Mar, 2022
What are the growth opportunities in Pharmaceutical Drug Delivery Market?.
Frank
Mar, 2022
Can you enlighten us on the end users in Pharmaceutical Drug Delivery Market?.